A Phase 4 interventional study of Poractant Alfa in Respiratory Distress Syndrome, Newborn and Premature Birth, sponsored by Endeavor Health. Recruiting at 1 site in United States. Open to participants aged Up to 15 Minutes, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by Endeavor Health · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Respiratory Distress Syndrome, Newborn · United States.
Among the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States, this one is the 8th largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 4, and was the 31st registered.
123 studies on the registry are indexed under Respiratory Distress Syndrome, Newborn; 24 are open to participants now.
Browse Respiratory Distress Syndrome, Newborn studies →5 of the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States are open now. Recruiting first, the newest first:
Hackensack Meridian Health · Sites in United States
Ages 27 wk–34 wk
Mayo Clinic · Sites in United States
Ages 32 wk–41 wk · Healthy volunteers
Connecticut Children's Medical Center · Sites in United States
Ages 0 hrs–2 hrs
Keck School of Medicine of USC · Sites in United States
Ages 1 hrs–24 hrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Respiratory Distress Syndrome, Newborn studies recruiting now, 2 (17%) set no upper age limit and 10 (83%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.
This study: Up to 15 Minutes · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 4 · Phase 4 5
First in 1995; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 90 across 93 interventional studies indexed under Respiratory Distress Syndrome, Newborn.
Median enrollment 93 across the 29 interventional studies, 500 across the 5 observational. Of the 25 that completed or were terminated, 7 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 34 have an industry lead sponsor. The 10 most frequent:
Endeavor Health is the lead sponsor of 111 studies on the registry; 34 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
Endeavor Health has 1 study filed under Respiratory Distress Syndrome, Newborn — fewer than ten, so there is no comparison to draw.
1 of the studies in Respiratory Distress Syndrome, Newborn with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06446453Connecticut Children's Medical CenterEchography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to explore the question: Does prophylactic administration of exogenous surfactant in the delivery room, using a minimally-invasive technique, improve outcome in preterm infants 22-29 weeks' gestation compared to rescue treatment using the same technique?
RESEARCH DESIGN Multicenter, randomized, controlled trial.
Northshore Evanston Hospital will be the primary site. It is hoped that Northwest Community, University of Chicago, Edwards Hospital, Advocate Park Ridge, Advocate Oak Lawn and Advocate Illinois Masonic will also join the study.
RECRUITMENT Entry criteria Inborn preterm infants 22 0/7-29 6/7 weeks' gestation, with be randomized to prophylactic Minimally Invasive Surfactant Therapy (MIST) in the delivery room compared to rescue MIST if fraction of inspired oxygen (FiO2) ≥0.30 at less than 48 hours of age. Babies in both groups will be managed on nasal continuous positive airway pressure (NCPAP) pressures of 5-8 cm water.
Exclusion criteria Infants will be excluded if there is a congenital anomaly or an alternative cause for respiratory distress.
Babies who require emergent intubation in the delivery room will not be enrolled in the interventions.
Parental Consent will be obtained prior to birth. Once delivery is imminent infant will be randomized to immediate versus rescue surfactant administration via MIST. Randomization will be in blocks of 6 and using cards with created by a web based randomizer.
Infants who require emergent intubation in the delivery room will not be enrolled in the interventions but their clinical outcomes will be assessed the same as the babies who receive the intervention.
There will be three gestational age strata (22-23 weeks, 24-26 weeks and 27-29 weeks). Twins and higher order multiples will be randomized independently. Babies in the lowest gestational age strata will not be enrolled at a center until 5 babies at that center have been enrolled in either of the other groups.
INTERVENTION Infants randomized to prophylactic surfactant treatment will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16 Gauge Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg as soon as possible after delivery (within 15 minutes). The infants will be stabilized and placed on NCPAP or High flow Nasal Cannula (HFNC).
Briefly the MIST procedure is as follows: the angiocath is inserted to an appropriate depth under direct laryngoscopy, the laryngoscope is removed, a carbon dioxide (CO2) detector is placed on the end of the catheter with a endotracheal tube adaptor. If the color changes then adaptor and detector are removed and the surfactant is instilled over about 1 minute and the catheter is removed. The infant is maintained on NCPAP/HFNC during the procedure.
Infants of both groups will be supported via HFNC or NCPAP in the delivery room and then transitioned to NCPAP in the neonatal intensive care unit (NICU).
The control group will be given surfactant via MIST if their fiO2 reaches a threshold of ≥30% within the first 48 hours of life.
A second dose of poractant alfa (Curosurf), at a dosage of 100mg/kg, will be administered via MIST to both groups if their fiO2 reaches the threshold of 30% between 6 and 48 hours after the first dose.
No further surfactant should be given in the first 7 days unless the infant reaches the intubation criteria.
POST-INTERVENTION MANAGEMENT Other than the requirement to adhere to intubation criteria in the first week, and in some cases perform a room air trial at 36 weeks corrected gestation, management will be at the discretion of the clinical team.
Titration of CPAP pressure is encouraged, with a permitted maximum of 8 cm H2O. Use of nasal intermittent positive-pressure ventilation (NIPPV) is allowable for apnea, but discouraged for Respiratory Distress Syndrome (RDS) and should only be after at least one dose of surfactant has been given.
Early caffeine therapy is expected.
Criteria for intubation:
Enrolled infants on CPAP will be intubated if:
These criteria apply during the first week of life, and to the first episode of intubation only. If the infant is intubated it is expected that another dose of surfactant will be administered.
OUTCOMES Primary outcome: Intubation in the first 7 days of age.
Secondary outcomes:
The above data will be collected until discharge. Babies born between 22 and 29 weeks are routinely followed by our developmental follow up clinic. The information from the 2-year developmental clinic visit will be recorded by the study.
SAMPLE SIZE 200, 50 being from NorthShore. Between 2018 and 2022 65% of the babies in this gestational age had an endotracheal tube inserted at Evanston Hospital, and were ventilated. Detection of a reduction of 25% (from 65% to 40%) with a 90% power and α = 0.05 (two-sided) would require 82 subjects per arm. It is anticipated that patient recruitment should take 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Infants randomized to prophylactic surfactant treatment will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg as soon as possible after delivery (within 15 minutes).
Drug: Poractant Alfa
The control group will be given surfactant will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg if their fiO2 reaches a threshold of ≥30% within the first 48 hours of life.
Drug: Poractant Alfa
Poractant alfa (Curosurf) 200mg/kg administered under direct laryngoscopy using a surfactant instillation catheter
Also known as: Minimally Invasive Surfactant Therapy
Endotracheal Intubation
Oxygen requirement \> 45% requiring endotracheal intubation
Time frame: 7 days
Bronchopulmonary dysplasia
Oxygen requirement to 36 weeks corrected age
Time frame: 36 weeks corrected gestational age
Plan to share: No
Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Poractant alfa
Respiratory Distress Syndrome, Newborn →